Canstatin,which possesses a significant inhibition effect on the migration of endothelial cells and a strong anticancer effect [1,2],has been applied in the treatment of many cancers including human oral,breast,prostate,pancreatic,and colorectal [3-7].However,because the expression of bioactive recombinant canstatin is very low using the current expression systems,e.g.prokaryotic Escherichia coli expression system [6],its application has still been limited to clinical trials.Several eukaryotic cell expression systems have been exploited for canstatin production,such as Bombyx mori cells [8] and Drosophila melanogaster S2 cells [9],but they also have a lot of disadvantages,for example,high culture cost,poor yield,and difficulty in purification.Therefore,it is necessary and urgent to develop an optimal expression system for the large-scale production of the recombinant canstatin.
展开▼
